Dr. Guy Cinamon is a skilled scientist, with over 15 years of diverse experience in biopharma, as a leader of innovative R&D teams and programs. He received his Ph.D. from the Weizmann Institute of Science, where his research focused on immune cell migration and activation and culminated in multiple high-impact publications. Following a successful post-doctorate fellowship at UCSF, Guy returned to Israel and joined Teva Pharmaceutical, where he served as a Director and Project Champion. In this role Guy led many initiatives in the field of oncology, auto-immune diseases, and inflammation, overseeing all aspects of drug development from pre-clinical and translational work to early-stage clinical trial management. Guy next moved to Quiet Therapeutics, where he held a position of GM and VP Pre-Clinical, leading the development of nanoparticle-based oncology targeted therapy. Dr. Cinamon joined Nectin Therapeutics in 2017 as VP R&D. In this role he is managing the development of several up-and-coming IO drug programs.